You are here

  • Home
  • Archive
  • Volume 78, Issue 1
  • Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Article info

Article menu
Download PDFPDF
Letter
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

Authors

  • Andrew L Mammen Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Arun Rajan Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Katherine Pak Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Tanya Lehky Electromyography Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Livia Casciola-Rosen Division of Rheumatology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Renee N Donahue Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Lauren M Lepone Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Anastasia Zekeridou Neuroimmunology Laboratory, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  • Sean J Pittock Neuroimmunology Laboratory, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  • Raffit Hassan Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Jeffrey Schlom Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • James L Gulley Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Andrew L Mammen, Muscle Diseases Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA; andrew.mammen{at}nih.gov
View Full Text

Citation

Mammen AL, Rajan A, Pak K, et al
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
Annals of the Rheumatic Diseases 2019;78:150-152.

Publication history

  • Received May 15, 2018
  • Revised July 20, 2018
  • Accepted July 30, 2018
  • First published September 5, 2018.
Online issue publication 
December 18, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.